Drug
HS-20089
HS-20089 is a pharmaceutical drug with 3 clinical trials. Currently 3 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(100%)
Phase Distribution
Ph phase_3
1
33%
Ph phase_1
1
33%
Ph phase_2
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)
Trials by Status
recruiting3100%
Recent Activity
3 active trials
Showing 3 of 3
recruitingphase_3
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
NCT06855069
recruitingphase_2
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
NCT06014190
recruitingphase_1
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
NCT06336707
Clinical Trials (3)
Showing 3 of 3 trials
NCT06855069Phase 3
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
NCT06014190Phase 2
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
NCT06336707Phase 1
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3